Latest news with #GaineyMcKenna&Egleston
Associated Press
5 days ago
- Business
- Associated Press
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. (URGN)
By Gainey McKenna & Egleston Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired UroGen Pharma Ltd. ('EuroGen' or the 'Company') (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the 'Class Period'). The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. Investors who purchased or otherwise acquired shares of EuroGen should contact the Firm prior to the July 28, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] . Please visit our website at for more information about the firm. The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.
Associated Press
14-03-2025
- Business
- Associated Press
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Geron Corporation ('Geron' or the 'Company') (NASDAQ: GERN) securities between June 7, 2024 and February 25, 2025, inclusive (the 'Class Period'). The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company created the false impression that they possessed reliable information pertaining to its projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations; (ii) in truth, the Company's optimistic reports of Rytelo's launch success and potential growth fell short of reality as the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied; and (iii) Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting. The Complaint further alleges that on February 26, 2025, the Company announced its financial results for the fourth quarter of fiscal year 2024, disclosing that Rytelo's growth had flattened over the preceding months, attributing the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the Company's stock price declined more than 32%. Investors who purchased or otherwise acquired shares of Geron should contact the Firm prior to the May 12, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
